Wegovy Side Effects: A Complete Guide to the 2.4 mg Obesity Dose

Common Wegovy Side Effects: The STEP Trial Picture

Wegovy is the brand name for semaglutide 2.4 mg, FDA-approved as a once-weekly subcutaneous injection for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. It is not interchangeable with Ozempic, which contains semaglutide at doses up to 2.0 mg and is approved for type 2 diabetes — a distinction that matters when interpreting side-effect frequency and severity at the higher obesity dose.

Across the four phase 3 STEP (Semaglutide Treatment Effect in People with Obesity) trials, gastrointestinal events were by far the most frequently reported adverse effects at the 2.4 mg dose. In STEP 1 — which enrolled approximately 1,961 participants — Wilding and colleagues reported the following rates in the semaglutide group compared with placebo:

• Nausea: approximately 44% vs 16%
• Diarrhea: approximately 30% vs 16%
• Vomiting: approximately 24% vs 6%
• Constipation: approximately 24% vs 11%

The large majority of these events were mild to moderate in intensity and were most pronounced during dose escalation. Fewer than 5% of STEP 1 participants on semaglutide discontinued treatment because of GI side effects.

Nausea at the Wegovy 2.4 mg Dose

Nausea is the single most reported side effect of Wegovy. It arises because semaglutide activates GLP-1 receptors in the gut and brainstem, slowing gastric emptying and amplifying satiety signaling — the same mechanism responsible for its weight-loss effect.

Nausea typically intensifies in the first few days after each dose increase, then eases over the following one to two weeks as the body adapts. Most people find it becomes manageable or resolves once the 2.4 mg maintenance dose is reached and stabilized.

Strategies that may reduce nausea:

• Eat smaller portions and chew food slowly and thoroughly
• Avoid high-fat, fried, or heavily spiced foods — especially around injection day
• Do not lie down immediately after eating
• Sip clear fluids between meals rather than drinking large amounts with food
• Inject on a consistent day each week; some people tolerate evening injections better

If nausea is severe or prevents adequate hydration, contact your provider. The escalation schedule can be extended under clinical guidance.

Diarrhea and Constipation on Wegovy

Wegovy can push gut motility in either direction. Diarrhea — reported in roughly three in ten STEP 1 participants on semaglutide — tends to occur earlier in treatment and often correlates with dose increases. It is usually transient; temporarily reducing greasy or very high-fiber foods and staying well hydrated can help.

Constipation was reported at a similar frequency and may be more persistent for some people. Reduced caloric intake, lower dietary fiber during the adjustment period, and slower gastric transit all contribute. Helpful steps include:

• Maintaining adequate daily fiber from fruits, vegetables, and whole grains
• Drinking at least 6–8 cups of water daily
• Gentle movement such as walking to support gut motility
• Asking your provider about a fiber supplement or stool softener if symptoms persist

Both conditions typically improve as the body adjusts to the medication and dietary intake stabilizes.

Gallbladder Events and Resting Heart Rate

Gallbladder disease: The Wegovy FDA prescribing information identifies cholelithiasis (gallstones) and other gallbladder-related disorders as adverse reactions observed at a higher rate in clinical trials than with placebo. Rapid weight loss independently increases gallstone risk by altering bile composition, making it difficult to fully separate the drug effect from the weight-loss effect. Patients with prior gallbladder disease should discuss this risk with their provider before starting treatment. Symptoms requiring prompt evaluation include right-upper-quadrant pain, fever, nausea after a fatty meal, or yellowing of the skin or eyes.

Resting heart rate: A modest increase in resting heart rate was documented across the STEP trials and is noted in the Wegovy prescribing information — consistent with a GLP-1 receptor agonist class effect. For most patients, the increase is small and not considered clinically significant. Individuals with pre-existing arrhythmias should discuss this with their provider. In broader context, the SELECT cardiovascular outcomes trial found that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in adults with established cardiovascular disease and obesity, indicating a net cardiovascular benefit in high-risk patients.

Injection-Site Reactions and Other Common Effects

Beyond the GI tract, the Wegovy prescribing information lists several other adverse effects:

• Injection-site reactions: redness, bruising, swelling, or mild discomfort at the injection site are common with any subcutaneous injectable. Rotating between the abdomen, thigh, and upper arm reduces local irritation.
• Headache: reported more frequently with semaglutide than placebo in STEP; typically mild and short-lived.
• Fatigue: some patients report low energy, particularly early in treatment or after dose increases.
• Belching and dyspepsia: consistent with slowed gastric emptying; usually manageable with dietary adjustments.
• Hypersensitivity reactions: rare, but serious allergic reactions including anaphylaxis and angioedema have been reported. Seek emergency care if you develop facial swelling, hives, or difficulty breathing after an injection.

Most of these effects are manageable and do not typically require stopping treatment.

Why Side Effects Peak During the 16–20-Week Dose Escalation

Wegovy follows a structured five-step escalation: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, with approximately four weeks at each step. This brings the total escalation period to roughly 16–20 weeks before reaching the full maintenance dose.

Side effects cluster in this window because each dose increase exposes the body's GLP-1 receptors — in the gut, brainstem, and elsewhere — to higher drug concentrations for the first time. Gastric emptying slows further, satiety signaling intensifies, and the GI tract responds with the transient nausea, loose stools, or constipation described in earlier sections.

Once the 2.4 mg steady-state concentration is reached, the body adapts and most people experience a meaningful reduction in side-effect burden. This is why following the escalation schedule — and not advancing doses too quickly — is important. If side effects at a given step are intolerable, your provider can extend the time at that dose before moving forward.

Pancreatitis: A Rare but Serious Risk

Acute pancreatitis — sudden inflammation of the pancreas — is a serious adverse event listed in the Wegovy prescribing information. Cases were reported in both the semaglutide and placebo arms of the STEP trials; a direct causal relationship has not been conclusively established, but the FDA label includes a warning and recommends discontinuation if pancreatitis is confirmed.

Warning signs to recognize immediately:

• Sudden, severe pain in the upper or middle abdomen
• Pain that radiates to the back
• Pain that worsens after eating
• Nausea and vomiting alongside the abdominal pain

If you experience these symptoms while taking Wegovy, stop the injection and seek emergency care immediately. Do not restart semaglutide without explicit guidance from your provider.

Patients with a personal history of pancreatitis, heavy alcohol use, or severely elevated triglycerides — which independently raise pancreatitis risk — should have a thorough discussion with their provider before starting Wegovy.

Boxed Warning: Thyroid C-Cell Tumors and Who Should Not Use Wegovy

Wegovy carries a boxed warning — the FDA's most serious caution — regarding thyroid C-cell tumors. In rodent studies, semaglutide caused dose- and duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this risk translates to humans is not established, as the relevance of rodent GLP-1 receptor thyroid expression to humans is uncertain. Nonetheless, the risk cannot be excluded.

Wegovy is contraindicated in patients with:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

All patients should be counseled to report the following symptoms promptly:

• A lump or swelling in the neck
• Hoarseness or persistent difficulty swallowing
• Shortness of breath
• Ongoing neck pain

Providers should screen for personal and family history of these conditions before prescribing. Routine thyroid monitoring is not required in patients without identified risk factors.

Hypoglycemia, Drug Interactions, and When to Seek Care

Hypoglycemia: Used alone for weight management, Wegovy does not typically cause hypoglycemia because it enhances insulin secretion in a glucose-dependent manner. However, risk increases significantly when Wegovy is combined with insulin or a sulfonylurea. Patients with type 2 diabetes who begin Wegovy may need their diabetes medications adjusted downward. Signs of low blood sugar include shakiness, sweating, confusion, and a rapid heartbeat.

Who should not take Wegovy:

• Personal or family history of MTC or MEN 2 (see boxed warning above)
• Known hypersensitivity to semaglutide or any ingredient in the formulation
• Pregnancy: weight-loss therapy is not recommended during pregnancy; discontinue if pregnancy is detected

A note on compounded semaglutide: Compounded semaglutide products are not FDA-approved and were not evaluated in the STEP clinical trials. The safety and efficacy data supporting Wegovy are specific to the FDA-approved 2.4 mg formulation. Patients should discuss the regulatory and clinical quality differences with their provider before considering any compounded alternative.

When to contact your provider or seek emergency care:

• Persistent vomiting or inability to keep fluids down
• Severe abdominal pain (possible pancreatitis or gallbladder event)
• Signs of a serious allergic reaction: hives, facial swelling, or difficulty breathing
• A new lump or swelling in the neck, or new hoarseness
• Changes in vision
• Thoughts of suicide or self-harm, listed under warnings and precautions in the FDA prescribing information